Carbohydrate intake prior to oral glucose tolerance testing

Klara R. Klein MD, PhD¹, Christopher P. Walker PhD²³, Amber L. McFerren²³, Halie Huffman², Flavio Frohlich PhD²⁷, and John B. Buse MD, PhD¹

¹Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

²Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

³Carolina Center for Neurostimulation, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

⁴Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

⁵Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

⁶Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

⁷Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Corresponding Author: Klara R. Klein, MD, PhD, Division of Endocrinology and Metabolism, Campus Box #7172, 8072 Burnett Womack, 160 Dental Circle, Chapel Hill NC 27599, Tel: (919)-966-0134, Fax (919)-966-6025, E-mail: klara_klein@med.unc.edu

Conflict of interest. The authors declare no relevant conflicts of interest.
ABSTRACT

With the emergence of glycated hemoglobin as a diagnostic test for diabetes, oral glucose tolerance tests (OGTTs) have become rare in endocrinology practice. As they have moved out of favor, the importance of patient instructions on preparation prior to OGTT has faded from memory. Decades old literature, well known to endocrinologists a generation ago, emphasize the importance of carbohydrate intake prior to OGTT. In this expert endocrine consult, we discuss an OGTT performed in a research setting without adequate carbohydrate intake at the evening meal prior to the OGTT. The resultant elevated plasma glucoses at 1-hour and 2-hours mimicked the loss of first-phase insulin release seen in early type 1 and type 2 diabetes. With clinical concern that the research participant had evolving type 1 or type 2 diabetes, the volunteer was subjected to additional testing and experienced anxiety. Repeat OGTT was normal after adequate carbohydrate intake (>150 grams/day and >50 grams the evening prior to overnight fast for the study). The physiology of this phenomenon is explored and is likely mediated through beta-cell adaptation and alteration in peripheral glucose uptake in response to nutrient exposure. The learnings of decades ago have clearly faded, and this literature should be revisited to ensure that OGTT results are not compromised when ordered for clinical or research purposes.

Key words: Oral glucose tolerance test, low carbohydrate, diabetes, impaired glucose tolerance.
The acceptance of glycated hemoglobin (HbA1c) for the diagnosis of diabetes and prediabetes has reduced the number of oral glucose tolerance tests (OGTTs) being performed in non-pregnant adults. With its limited use, the importance of proper preparation prior to administration of an OGTT, well established long ago, has faded from the literature and guidelines. In this expert endocrine consult, we report a false-positive OGTT in the setting of a single low carbohydrate meal prior to testing and underscore a literature that has been forgotten over a generation but has important implications in both clinical care and research.

Case Report

A 20-year-old healthy woman volunteered for a research study that required patients with no history of diabetes to undergo an OGTT in order to evaluate the effect of circulating glucose on neuronal excitability. A physically active college student, the volunteer had a BMI 20.7 kg/m² and no personal or family history of diabetes. At screening, her fasting plasma glucose (PG) was 71 mg/dL. She qualified for the study and was instructed to fast for 12 hours prior to presentation. At the study visit, fasting PG was 60 mg/dL. A 75-gram OGTT was performed in a research setting by experienced staff. One-hour post-glucose load, PG was 153 mg/dL (Table 1). Two hours post-glucose load, PG was 200 mg/dL (Table 1).

Given concern that this test result indicated the diagnosis of diabetes, a medical history and extensive dietary recall was obtained. The day prior to the abnormal OGTT, she reported eating a high carbohydrate breakfast and lunch from a fast-food restaurant that included French fries. Dinner consisted of eggs, turkey bacon, avocado on toast, and 8 ounces of orange juice (less than 50 grams net carbohydrates). She confirmed that she had no risk factors for type 2 diabetes, no history of disordered eating, and no family or personal history of autoimmunity. She acknowledged anxiety about the potential diagnosis of diabetes.
Two national diabetes experts focused in type 1 diabetes prevention and management were presented the findings and decades old literature that suggest that a low carbohydrate diet (<150 grams/day and <50 grams prior to fasting for the test) can lead to false positive OGTTs. Both experts acknowledged the literature regarding carbohydrate loading prior to OGTT, but suggested that the presentation was consistent with early (stage 2) type 1 diabetes (1). Each recommended antibody testing as well as a repeat OGTT after appropriate and documented dietary preparation.

One week after she was informed of the abnormal OGTT, the patient repeated a 75-gram OGTT in a primary care setting. She was instructed to eat a minimum of 150 grams carbohydrates for three days prior to testing. She completed a food log that was confirmed to document >50 grams carbohydrate per meal by her physician. Blood was collected for HbA1c and GAD65 antibodies. Repeat OGTT revealed a fasting PG of 71 mg/dL (Table 1). Two hours post 75-gram glucose load, PG was 75 mg/dL (Table 1). HbA1c was 5.0% (31 mmol/mol). GAD65 antibodies were negative. The patient met no criteria for diabetes or prediabetes on repeat testing.

Discussion

“Hunger diabetes” was first described in the late 18th century after the discovery of glucosuria in starving dogs fed a high carbohydrate meal (2). Fifty years later, the clinical importance of diet prior to OGTT was described. Well- and under-nourished individuals who had normal glucose tolerance after a five-day 300 gram carbohydrate preparatory diet were restricted to 20 grams carbohydrate for five days (2). Restriction of carbohydrates resulted in delayed clearance of absorbed glucose in all individuals and was exaggerated in undernourished participants. After low carbohydrate diets, all undernourished individuals met criteria for glucose intolerance or diabetes. Dr. Conn thus recommended a standard 300-gram carbohydrate diet prior to OGTT.
Wilkerson et al. challenged that a 150-gram carbohydrate diet is sufficient in most normally nourished individuals. Restriction of carbohydrates to 20 grams for five days resulted in impaired glucose tolerance (IGT) in males and females (3). Twenty two percent of women (two out of nine) and no men met criteria for diabetes, suggesting that sex differences may exist in glucose tolerance in response to carbohydrate restriction (3). Based on these data, the World Health Organization (WHO) has long recommended preparation for OGTT with greater than 150 grams carbohydrate per day (4). This recommendation, buried in the appendix of the 1985 WHO report, has been minimized further in updates. The current American Diabetes Association (ADA) Standards of Care cite the WHO report, but the document does not explicitly state the need for dietary guidance prior to OGTT (5). Similarly, the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) guidelines for the diagnosis of diabetes do not mention the necessary carbohydrate loading prior to testing (6). Notably, the 2008 ACE/AACE guidelines for the diagnosis and management of prediabetes indicates the necessity of adequate carbohydrate intake prior to OGTT but does not define the amount of carbohydrate required (7).

More recent data, though still over twenty years old, demonstrated that some individuals who ate a normal carbohydrate breakfast and lunch (60% carbohydrate, >75 grams) followed by a low carbohydrate dinner (10% carbohydrate, <50 grams) exhibited IGT, even when the daily carbohydrate totaled greater than 150 grams (8). In this study, all participants (eight men and four women) had normal fasting glucose irrespective of their carbohydrate intake. All participants had normal glucose tolerance the morning after a single high-carbohydrate meal (80% carbohydrate, >100 grams). However, despite a daily total of ≥150 grams carbohydrate, 38% of men (3 out of 8) and 25% of women (1 out of 4) demonstrated impaired glucose tolerance after a single low-carbohydrate meal (<50 grams) immediately prior to testing. These data are consistent with the case presented here, where the patient ate greater than 150 grams carbohydrates daily, but limited carbohydrates in her
final meal prior to the abnormal OGTT. We are not aware of any guideline that explicitly states the necessity of a normal-to-high carbohydrate meal (50 grams minimum) immediately prior to the fasting period before presentation for the OGTT.

OGTTs are ordered less frequently by clinical endocrinologists. Conversely, obstetricians order OGTTs on nearly all pregnant non-diabetic patients. While some studies suggest that carbohydrate loading does not affect the OGTT in pregnancy (9-11), none of these studies compare confirmed low carbohydrate diets (less than 150 grams/day) to higher carbohydrate diets. Moreover, similar to the case presented here, a very low carbohydrate meal (6.7% carbohydrate, <10 grams) immediately prior to OGTT has been shown to alter OGTT results during pregnancy (12). Recent data also suggests that low carbohydrate diets are associated with positive 1-hour OGTT and diagnosis of gestational diabetes in pregnancy diabetes screening programs (13, 14). As gestational diabetes diagnosis is increasing, some of the obstetrics community recognizes the flawed nature of OGTT and posits that alternative screening tools will eventually replace the OGTT for detection of gestational diabetes (15). Until then, more research to understand how carbohydrate intake impacts OGTT in pregnancy is warranted and a standardized protocol for OGTT preparation is essential.

The mechanisms of how low-carbohydrate diets impact glucose metabolism are complex and incompletely understood. Some propose that the mechanism is in part due to loss of first phase insulin release resulting in decreased peripheral and hepatic glucose uptake and incomplete suppression of hepatic glucose production (16-18). Loss of first phase insulin is well characterized in both type 1 and type 2 diabetes and occurs early in the evolution of diabetes (19, 20). Investigators in the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1) identified a subgroup of individuals with islet cell antibodies and impaired first phase insulin response, who were asymptomatic and had normal fasting PG, but who were diagnosed with diabetes via OGTT (21). Loss of first phase insulin release is also well documented in type 2 diabetes, though whether it precedes insulin resistance has been
debated (20). Hyperglycemic clamp experiments in individuals with IGT demonstrate loss of first and second phase insulin release (20, 22). First phase insulin release is reduced to a greater degree than second phase insulin release, suggesting that the primary defect may start with first phase insulin loss. Insulin sensitivity was also decreased in individuals with IGT, but to a lesser extent, suggesting that type 2 diabetes is defined first by beta cell dysfunction, rather than insulin resistance (20). Indeed, seminal work led by John Gerich demonstrates that subjects with normal glucose tolerance and a first degree relative with type 2 diabetes have decreased first and second phase insulin release without a defect in insulin sensitivity (20, 23). Though supportive data is limited, as no insulin levels were drawn during the study, the OGTT presented here after a single low carbohydrate meal appears to mimic first phase insulin loss, suggesting that low-carbohydrate intake may impact beta-cell function.

Few mechanistic studies employ single low-carbohydrate meals to explore the impact of carbohydrate intake on glucose metabolism. Data from longer-term low-carbohydrate or ketogenic diets therefore provide insight. Animal models have shown that longer-term low carbohydrate diets result in decreased beta cell mass (24) that is likely reversible (25, 26). Rats that are fed low-carbohydrate high-fat (LC-HF) or ketogenic diets where 5% or less of total calories are derived from carbohydrates for three to eight weeks demonstrate a significant increase in glucose levels during OGTT (24, 26). Caloric restriction of LC-HF diets to 80% of the isoenergetic pair-fed groups eliminated differences in fat mass, but glucose intolerance was maintained in LC-HF animals, suggesting that adiposity was not the driver of abnormal glucose metabolism (24). Instead, total pancreas volume and total beta-cell volume was significantly lower in LC-HF diet fed rats compared to controls (24). The cause of this loss of beta-cell mass is multifactorial, but loss of insulin- and hyperglycemia-mediated pro-proliferative and hypertrophic effects likely contribute (27-30). Unlike the primary beta cell defect observed in type 1 and type 2 diabetes, studies have demonstrated
that the beta cell dysfunction caused by low carbohydrate diets are likely reversible, as resumption of normal carbohydrate diet restores glucose homeostasis (26).

Low carbohydrate intake also impacts insulin sensitivity in both animal models and humans. Euglycemic clamp studies in rats and mice fed ketogenic diet for three to eight weeks demonstrate impaired hepatic and peripheral insulin sensitivity (24, 31) When fed a ketogenic diet, both rodent models required a significantly lower glucose infusion rate to maintain a euglycemic clamp, indicating whole body insulin resistance (24, 31). Additionally, the ability of the glucose infusion to suppress endogenous glucose production was significantly impaired compared to regular chow fed animals, suggesting hepatic specific insulin resistance (24, 31). Similar hepatic insulin resistance has been shown in mice following only three days of ketogenic diet (32).

In humans, data in highly trained athletes who were subjected to six months of low carbohydrate, high fat diets (~50 grams/day carbohydrate), demonstrated high glucose concentrations and delayed peak insulin concentrations during OGTT and reduced expression of key proteins of the insulin signaling pathway, glucose transporter 4 (GLUT4) and insulin receptor substrate 1 (IRS1) (33). IRS1 phosphorylation initiates the insulin cascade, which is critical for translocation of GLUT4 to the plasma membrane and rapid uptake of glucose in the muscle (33). Loss of expression of these proteins results in an insulin-resistance-like state, which is unlikely pathological, but instead an adaptation to consistently reduced glucose exposure (33).

Additional mechanisms may also play a role, particularly in acute low-carbohydrate diets. For example, low carbohydrate diets are associated with an increase in plasma free fatty acids, which may decrease insulin secretion. Fatty acid oxidation is associated with decreased glycolysis, glucose uptake, and glucose oxidation, all of which can ultimately raise plasma glucose (17, 25, 34, 35). Alterations in the level of glucagon-like peptide 1 (GLP-1) have also been observed in association with low carbohydrate diets (20% of total
energy derived from carbohydrates). Short term low carbohydrate diets in healthy individuals have been shown to increase the levels of post-glucose load GLP-1, which may be in part to compensate for reduced insulin production (17, 36). Whether these mechanisms are caused by low-carbohydrate diet or are a result of changes in other metabolic parameters remains to be elucidated.

Nutrition research continues to investigate these mechanisms, particularly in regard to the long-term impact of low carbohydrate diets on metabolism and clinical disease (37). These efforts are essential, as ketogenic diets (<50 grams carbohydrate/day) and other lower carbohydrate meal plans have become increasingly popular. Yet, our understanding of the influence of these diets on the risk of metabolic disease is unknown. Meanwhile, despite a growing group of physicians arguing for increased oral glucose tolerance testing for the identification of dysglycemia (38), clinicians are forgetting that low carbohydrate diets may also impact a diagnostic tool, the OGTT.

The utility of HbA1c is unassailable, but like every test, it has flaws (39). A threshold of HbA1c >6.5% was suggested for the diagnosis of diabetes based on studies demonstrating an association between HbA1c and diabetic retinopathy, but data suggest that this HbA1c fails to identify a significant population of people with diabetes by OGTT or fasting PG (40, 41). AACE/ACE and ADA guidelines acknowledge limitations in HbA1c and fasting PG as tools for diagnosis of diabetes, implying that measuring PG after a 75 gram 2-hour OGTT may be the most sensitive test for detecting diabetes (42). Indeed, using HbA1c 6.5% for the diagnosis of diabetes has high specificity (~99%), but the sensitivity is poor (~20-40%) when compared to 75-gram OGTT (43). Moreover, two-hour PG has a strong association with cardiovascular disease, hypertension, dyslipidemia, and microalbuminuria (43). Failure to identify individuals with diabetes solely based on positive 2-hour PG risks under diagnosing and treating a population particularly vulnerable to cardiovascular disease.
HbA1c also fails to identify the majority of patients with impaired glucose tolerance (44) and early dysglycemia (43), leaving OGTTs as the posited most appropriate tool to identify these patients. Use of OGTT in high-risk patients allows for early intervention and prevention of progression to type 2 diabetes. As such, the ADA specifically recommends OGTT as the preferred method for diagnosis of cystic fibrosis-related diabetes, post-transplantation diabetes mellitus, and in the post-partum period in women with gestational diabetes and notes preferences among some authorities for the diagnosis of diabetes in children (45). The ADA also notes that PG measurements (fasting PG or 2-hr OGTT) should be used in conditions that alter the relationship of HbA1c and glyceremia, including but not limited to increased red blood cell turnover, HIV treated with certain protease inhibitors, and iron deficiency anemia (1). The Endocrine Society also recommends use of OGTT over HbA1c in women with polycystic ovarian syndrome, given the association between IGT and cardiovascular disease in women (46). Furthermore, emerging data suggest that impaired glucose tolerance identified by 2-hour PG provides prognostic information following myocardial infarction, whereas HbA1c and fasting PG do not, paving the way for expanding the use of OGTT to other circumstances (44).

The strength of 1-hour PG >155 mg/dL as an early marker of dysglycemia and predictor of incident diabetes, cardiovascular risk, diabetes complications, and mortality has emerged over the last several years (47-49). One-hour PG >155 mg/dL following a 75-gram OGTT is also more sensitive for detecting individuals at high risk for type 2 diabetes than HbA1c, fasting PG, or 2-hour PG (43). Individuals with normal glucose tolerance and a 1-hour PG >155mg/dL likely share abnormalities observed in IGT including β-cell dysfunction and impaired insulin sensitivity (43). The use of 1-hour OGTT may allow the identification of a vulnerable population that may otherwise be overlooked even by the gold standard 2-hour PG following 75-gram OGTT (50). As 1-hour PG as a diagnostic tool gains traction, clinical OGTT use may increase, and clinicians must be reminded of the testing requirements to permit proper interpretation.
Perhaps most importantly, as in the case presented here, OGTTs are increasingly used in research settings where investigators may not be aware of the importance of proper preparation. Using the search terms “oral glucose tolerance test” or “OGTT” on clinicaltrials.gov on March 11, 2021 yielded >1500 studies that report OGTTs as part of the study protocol. As awareness of appropriate instruction prior to OGTT is lost and investigators less knowledgeable about the issues discussed here employ OGTTs, study outcomes and their volunteers may be impacted. Investigators must therefore be made aware of the activities that can influence test results and contribute to the overall poor reproducibility of the test, especially with regard to the 2-hour post glucose load value (15, 51-53). These include patient factors (exercise, stress, sleep, smoking, hydration status, and caffeine, alcohol, and carbohydrate consumption) and proper collection, storage, and specimen sampling to prevent glucose metabolism following blood draw (15).

Conclusion

The case reported herein, supported by decades-old literature, demonstrates that the OGTT administered without full understanding or adherence to the specific protocol of preparation and administration can lead to false positive results, patient distress, and potentially the misdiagnosis of diabetes. More research is necessary to understand why a single low-carbohydrate meal impacts some individuals. In the meantime, as OGTT use increases in an era of low carbohydrate diets, provider and patient education about dietary preparation for OGTT should be explicit in order to avoid false positive test results. Guidance should also recommend against smoking, caffeine consumption, and exercise immediately prior to OGTT as they may also impact results (54-56). Importantly, patients should receive dietary instruction to prepare for the OGTT:

- at least 3 days of “unrestricted diet” (moderate to high carbohydrate intake), containing >150 grams of carbohydrates daily;
• ideally, the meal plan should be delivered as three daily meals containing at least 50 grams of carbohydrates per meal;
• perhaps most importantly, the last meal the evening before the fasting test should include at least 50 grams of carbohydrates;
• per WHO recommendations, “the test should be preceded by an overnight fast of 10-16 hours during which water may be drunk”.
Acknowledgements. This work was supported by funds from the NIH-supported Nutrition Obesity Research Center (NORC) grant P30DK56350 to F.F. and services from the NC Translational and Clinical Sciences Institute (UL1TR002489) and the North Carolina Diabetes Research Center (P30DK124723). K.K. is supported by the UNC Department of Medicine’s Physician Scientist Training Program. K.K. and J.B wrote the manuscript. CW, AMcF, HH, and FF participated in data collection. All authors approved the final version submitted. Finally, we are grateful to the reviewers and editors of the Journal of the Endocrine Society, who helped us improve the manuscript.

Conflict of interest. The authors declare no relevant conflicts of interest.

Data Availability Statement. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References

1. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S14-S31.

2. Conn. Interpretation of the glucose tolerance test. The necessity of a standard preparatory diet. The American journal of the medical sciences. 1940;199:555-64.

3. Wilkerson HLC, Butler FK, Francis JOS. The Effect of Prior Carbohydrate Intake on the Oral Glucose Tolerance Test. Diabetes. 1960;9(5):386-91.

4. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1985;727:1-113.

5. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.

6. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21 Suppl 1(Suppl 1):1-87.

7. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-46.

8. Kaneko T, Wang PY, Tawata M, Sato A. Low carbohydrate intake before oral glucose-tolerance tests. Lancet. 1998;352(9124):289.
9. Buhling KJ, Elsner E, Wolf C, Harder T, Engel B, Wascher C, et al. No influence of high- and low-carbohydrate diet on the oral glucose tolerance test in pregnancy. Clin Biochem. 2004;37(4):323-7.

10. Crowe SM, Mastrobattista JM, Monga M. Oral glucose tolerance test and the preparatory diet. Am J Obstet Gynecol. 2000;182(5):1052-4.

11. Entrekin K, Work B, Owen J. Does a high carbohydrate preparatory diet affect the 3-hour oral glucose tolerance test in pregnancy? J Matern Fetal Med. 1998;7(2):68-71.

12. Takizawa M, Kaneko T, Kohno K, Fukada Y, Hoshi K. The relationship between carbohydrate intake and glucose tolerance in pregnant women. Acta Obstet Gynecol Scand. 2003;82(12):1080-5.

13. Chen Q, Chen Y, Wu W, Tang N, Wang D, Chen Y, et al. Low-carbohydrate-diet and maternal glucose metabolism in Chinese pregnant women. Br J Nutr. 2020;1-22.

14. Zhou X, Chen R, Zhong C, Wu J, Li X, Li Q, et al. Maternal dietary pattern characterised by high protein and low carbohydrate intake in pregnancy is associated with a higher risk of gestational diabetes mellitus in Chinese women: a prospective cohort study. Br J Nutr. 2018;120(9):1045-55.

15. Bogdanet D, O'Shea P, Lyons C, Shafat A, Dunne F. The Oral Glucose Tolerance Test-Is It Time for a Change?-A Literature Review with an Emphasis on Pregnancy. J Clin Med. 2020;9(11).

16. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need
of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care. 2020;43(4):726-33.

17. Numao S, Kawano H, Endo N, Yamada Y, Konishi M, Takahashi M, et al. Short-term low carbohydrate/high-fat diet intake increases postprandial plasma glucose and glucagon-like peptide-1 levels during an oral glucose tolerance test in healthy men. Eur J Clin Nutr. 2012;66(8):926-31.

18. Swinburn BA, Boyce VL, Bergman RN, Howard BV, Bogardus C. Deterioration in carbohydrate metabolism and lipoprotein changes induced by modern, high fat diet in Pima Indians and Caucasians. J Clin Endocrinol Metab. 1991;73(1):156-65.

19. Bingley PJ. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes. 1996;45(12):1720-8.

20. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002;51 Suppl 1:S117-21.

21. Greenbaum CJ, Cuthbertson D, Krischer JP, Disease Prevention Trial of Type IDSG. Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes. 2001;50(2):470-6.

22. van Haeften TW, Pimenta W, Mitrakou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, et al. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism. 2000;49(10):1318-25.
23. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273(23):1855-61.

24. Bielohuby M, Sisley S, Sandoval D, Herbach N, Zengin A, Fischereider M, et al. Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. Am J Physiol Endocrinol Metab. 2013;305(9):E1059-70.

25. Caminhotto Rde O, Lima FB. Impaired glucose tolerance in low-carbohydrate diet: maybe only a physiological state. Am J Physiol Endocrinol Metab. 2013;305(12):E1521.

26. Kinzig KP, Honors MA, Hargrave SL. Insulin sensitivity and glucose tolerance are altered by maintenance on a ketogenic diet. Endocrinology. 2010;151(7):3105-14.

27. Her TK, Lagakos WS, Brown MR, LeBrasseur NK, Rakshit K, Matveyenko AV. Dietary carbohydrates modulate metabolic and beta-cell adaptation to high-fat diet-induced obesity. Am J Physiol Endocrinol Metab. 2020;318(6):E856-E65.

28. Okada T, Liew CW, Hu J, Hinault C, Michael MD, Krzfeldt J, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A. 2007;104(21):8977-82.

29. Stamateris RE, Sharma RB, Kong Y, Ebrahimpour P, Panday D, Ranganath P, et al. Glucose Induces Mouse beta-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor. Diabetes. 2016;65(4):981-95.

30. Terauchi Y, Takamoto I, Kubota N, Matsuji J, Suzuki R, Komeda K, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in
response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117(1):246-57.

31. Jornayvaz FR, Jurczak MJ, Lee HY, Birkenfeld AL, Frederick DW, Zhang D, et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am J Physiol Endocrinol Metab. 2010;299(5):E808-15.

32. Grandl G, Straub L, Rudigier C, Arnold M, Wueest S, Konrad D, et al. Short-term feeding of a ketogenic diet induces more severe hepatic insulin resistance than an obesogenic high-fat diet. J Physiol. 2018;596(19):4597-609.

33. Webster CC, van Boom KM, Armino N, Larmuth K, Noakes TD, Smith JA, et al. Reduced Glucose Tolerance and Skeletal Muscle GLUT4 and IRS1 Content in Cyclists Habituated to a Long-Term Low-Carbohydrate, High-Fat Diet. Int J Sport Nutr Exerc Metab. 2020:1-8.

34. Oprescu AI, Bikopoulos G, Naassan A, Allister EM, Tang C, Park E, et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes. 2007;56(12):2927-37.

35. Rosenbaum M, Hall KD, Guo J, Ravussin E, Mayer LS, Reitman ML, et al. Glucose and Lipid Homeostasis and Inflammation in Humans Following an Isocaloric Ketogenic Diet. Obesity (Silver Spring). 2019;27(6):971-81.

36. Numao S, Kawano H, Endo N, Yamada Y, Takahashi M, Konishi M, et al. Short-term high-fat diet alters postprandial glucose metabolism and circulating vascular cell adhesion molecule-1 in healthy males. Appl Physiol Nutr Metab. 2016;41(8):895-902.
37. Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS. A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD. Obesity (Silver Spring). 2020;28(10):1843-52.

38. LeRoith D, Halter JB. Diagnosis of Diabetes in Older Adults. Diabetes Care. 2020;43(7):1373-4.

39. Klein KR, Buse JB. The trials and tribulations of determining HbA1c targets for diabetes mellitus. Nat Rev Endocrinol. 2020;16(12):717-30.

40. Jagannathan R, Buysschaert M, Medina JL, Katz K, Musleh S, Dorcely B, et al. The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia. Acta Diabetol. 2018;55(6):519-29.

41. Jagannathan R, Neves JS, Dorcely B, Chung ST, Tamura K, Rhee M, et al. The Oral Glucose Tolerance Test: 100 Years Later. Diabetes Metab Syndr Obes. 2020;13:3787-805.

42. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S14-S31.

43. Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV, et al. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract. 2020;165:108233.

44. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology. Diabetes Care. 2017;40(9):1233-40.

45. Professional Practice Committee: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S3.
46. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92.

47. Orencia AJ, Daviglus ML, Dyer AR, Walsh M, Greenland P, Stamler J. One-hour postload plasma glucose and risks of fatal coronary heart disease and stroke among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry (CHA) Study. J Clin Epidemiol. 1997;50(12):1369-76.

48. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008;31(8):1650-5.

49. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, et al. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired beta-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab. 2013;98(5):2100-5.

50. Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, et al. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose/>=155mg/dl (8.6mmol/L). Diabetes Res Clin Pract. 2018;146:18-33.

51. Liu M, Pan CY, Jin MM, Su HY, Lu JM. [The reproducibility and clinical significance of oral glucose tolerance test for abnormal glucose metabolism]. Zhonghua Nei Ke Za Zhi. 2007;46(12):1007-10.

52. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for
diabetes and other cardiovascular risk factors. Ann Clin Biochem. 1998;35 ( Pt 1):62-7.

53. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab. 2008;93(11):4231-7.

54. Frati AC, Iniesta F, Ariza CR. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. Diabetes Care. 1996;19(2):112-8.

55. Robinson LE, Savani S, Battram DS, McLaren DH, Sathasivam P, Graham TE. Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes. J Nutr. 2004;134(10):2528-33.

56. Rose AJ, Howlett K, King DS, Hargreaves M. Effect of prior exercise on glucose metabolism in trained men. Am J Physiol Endocrinol Metab. 2001;281(4):E766-71.
Experimental Protocol | Clinical exam
---|---
Screening | OGTT | OGTT
(low carb dinner) | (high carb diet)

| Time (m) | Glucose (mg/dL) | Glucose (mg/dL) | Glucose (mg/dL) |
|---|---|---|---|
| 0  | 71 | 60 | 71 |
| 30 | - | 153 | - |
| 60 | - | 153 | - |
| 120 | - | 200 | 75 |
| 180 | - | 152 | - |

Table 1. OGGT results. During the experimental protocol, single pulse transcranial magnetic stimulation and a working memory task was performed while high density EEG was recorded at each OGGT time point. The first OGGT was performed after a low carbohydrate (carb) dinner prior to a 12 hour fast before the study. The clinical exam OGGT was performed in a primary care setting after three days of >150 grams/day carbohydrate ingestion and specifically a high carbohydrate meal the night prior to the OGGT. OGGT = oral glucose tolerance test.